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Abstract Follicular Lymphoma (FL) is the secondmost com-
mon type of non-Hodgkin lymphoma and is considered to be
the prototype of indolent lymphomas. Histologic transforma-
tion into an aggressive lymphoma, which is expected to occur
at a rate of 2 to 3% each year, is associated with rapid progres-
sion, treatment resistance, and poor prognosis. Recent modi-
fications to the physiopathologic mechanism of transformed
follicular lymphoma (t-FL) have been proposed, including
genetic and epigenetic mechanisms as well as a role for the
microenvironment. Although t-FL is considered a devastating
complication, as it is associated with treatment-refractory dis-
ease and a dismal outcome, recent data in the rituximab era
have suggested that not only is the prognosis less severe than
reported in the previous literature but the risk of transforma-
tion is also lower. Thus, this study aimed to review the most
recent research on t-FL in an attempt to better understand the
clinical meaning of transformation from FL to diffuse large B
cell lymphoma (DLBCL) and the impact of current treatment
strategies on the curability of this intriguing subentity of
lymphoma.
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Introduction
Follicular Lymphoma (FL) is the second most common type of
non-Hodgkin lymphoma (NHL) in the USA and Europe (10–
20% of NHL), with approximately 15,000 newly diagnosed
cases per year [1, 2]. It is considered the prototype of indolent
lymphomas, has an equal distribution between men and wom-
en, and has a median age of 65 years at presentation [3–5].
These patients are frequently diagnosed at an advanced stage,
and bone marrow (BM) involvement is present in approxi-
mately 50% of the cases. Translocation t(14;18)(q32;q21)
places the antiapoptotic BCL-2 oncogene under the control
of the immunoglobulin (Ig) heavy-chain enhancer and is a
genetic hallmark of FL. The presence of this translocation
has been used recently to support diagnosis and to monitor
response to therapy [3, 6–12].
The occurrence of relapse characterizes the natural history
of FL, which has a shorter duration of remission at every
recurrence. Although major improvements have been
achieved with therapy, this type of lymphoma is still consid-
ered an incurable disease. Recently, however, the natural his-
tory of the disease has been measured in decades, and a high
proportion of FL patients will die due to reasons other than
lymphoma progression [3, 4, 13, 14].
In spite of the improvement in the diagnostic accuracy and
the efficacy of chemoimmunotherapy regimens, progression
and transformation still occur [15]. The 3-year progression-free
survival rate after chemoimmunotherapy is approximately
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50%, and the rate of transformation to more aggressive forms
of lymphoma is 2–3% per year [8, 16–23]. The most common
histologic subtype during transformation is diffuse large B cell
lymphoma (DLBCL), but other histological subtypes may be
seen such as Burkitt lymphoma (BL), lymphoblastic lympho-
ma, acute lymphoblastic leukemia, and occasionally, cases of
Hodgkin lymphoma [14, 15, 19, 24, 25].
It is important to emphasize that t-FL implies the existence
of a clonal relationship between the original FL and the sub-
sequent aggressive subtype [15]. It has been postulated that
the presence of the same immunoglobulin, immunoglobulin
segments, and common somatic mutations might contribute to
this relationship. In addition, other authors have suggested the
existence of a common progenitor cell (CPC) that may be
responsible for lymphoma persistence, resistance, recurrence,
and transformation [20, 26–28].
Although histologic transformation (HT) was first de-
scribed more than 65 years ago by Gall and Mallory, the bio-
logical and clinical events that characterize transformation re-
main incompletely understood, and many questions remain
unanswered [29]. Therefore, the objective of this review is
to focus on aspects of transformation to clarify the physiopa-
thology, diagnosis, prognostic factors, and treatment. This ef-
fort aims to offer a better understanding of HT in FL, and
consequently, to improve the chances of treatment
effectiveness.
Physiopathology of the transformation process
To better understand the biology of the transformation pro-
cess, it is important to rely on the transformation concept.
Therefore, HT refers to the evolution of a clinically indolent
NHL (i.e., FL) into a clinically aggressive lymphoma (i.e.,
DLBCL, Burkitt lymphoma, gray zone lymphoma or lympho-
blastic lymphoma, and other high-grade B cell lymphomas).
In addition to FL, transformation can also occur in other sub-
types of indolent lymphoma, such as marginal zone lympho-
ma, lymphoplasmacytic lymphoma, small lymphocytic
lymphoma/chronic lymphocytic leukemia, and lymphocyte
predominant Hodgkin lymphoma [14, 30].
Another important concept is that transformation is not
frequently a Blinear^ process that involves the subsequent ac-
cumulation of oncogenic mutations. In contrast, a Bnonlinear^
transformation, which begins with an immature precursor,
seems to be the rule rather than the exception [11] (Fig. 1).
Despite the existence of these two mechanisms, they are not
mutually exclusive and may be independently activated in the
same patient or even in the same lymph node [31] (Fig. 2).
Genetic alterations that are shared between FL and t-FL are
evidence of this clonal relationship [18, 31].
Previous studies have already demonstrated that t-FL most
commonly arises from immature CPCs and that these cells
may remain in BM niches during treatment, where they ac-
quire new genomic lesions [32–34]. Even though the exis-
tence of CPCs has not been physically demonstrated, it can
be postulated, and the genetic lesions that are shared between
FL and t-FL may help in the understanding of the sequence of
events [18]. This theory of cancer-initiating cells has been
previously described in epithelial cell cancers and is associat-
ed with the cell’s ability to self-renew, proliferate, and gain
resistance to chemical or physical insults [31, 32].
Recent genetic studies have contributed to the expansion of
the knowledge associated with transformation; however, the
sequence of successive genetic hits or simultaneous alterations
that produce an aggressive phenotype remains unclear [33].
The most common genetic lesions in FL and t-FL may be
classified into the following cell processes (Fig. 3):
& Programmed cell death–apoptosis: t(14;18) translocation
places the antiapoptotic BCL-2 oncogene under control of
the immunoglobulin (Ig) heavy-chain enhancer (IGH/
BCL-2) [10, 34]. This is a typical genetic lesion in FL;
however, this lesion alone seems to be insufficient for the
induction of clinical disease, which is reinforced by its
occurrence in healthy individuals [9, 35–37]. Moreover,
this t(14;18) translocation sufficiently lengthens the
lifespan of cells to permit the acquisition of secondary
alterations as well as other genetic mutations [38].
Mutated BCL-2 is seen at a higher frequency in t-FL,
which thus reaffirms the importance of the accumulation
of secondary alterations in the genesis of lymphoma [8].
It is important to emphasize that BCL-2 translocation
has been always described in FL and t-FL, and its occur-
rence ensures its participation in clonal precursor expan-
sion [18].
& Histone/chromatin modification enzymes (epigenetic reg-
ulators): methyltransferases–H3K3, MLL2, EZH2, and
acetytransferases–CREBBP, EP300.
Similar to BCL-2 translocation, CREBBP expression,
mutation, or the occurrence of some other alteration has
been described to occur at a high frequency. Each has a
uniform representation and functions as a Bdriver^ in t-FL
pathology. On the contrary, MLL2 has a variable represen-
tation, given its plausible function as an Baccelerator^ [38].
Therefore, the presence of alterations in MLL2 gives a
selective advantage to a given clone compared with other
competing clones [38].
The CREBBP and MLL2 genes were described as the
most commonly affected genes in clinical FL. Alterations
in these genes are present at diagnosis and are never lost
during progression or transformation, which also suggests
that they are early acquisitions by CPCs [18, 39].
& Cell cycle and DNA damage response: one of the most
important events in the transformation process is
CDKN2A/B loss, which is associated with inactivation
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of the p53 tumor suppression gene (DNA damage re-
sponse) and with expression of p16 protein (part of cycle
cell regulation). These cause changes in G1 phase of the
cell cycle and result in genomic instability [18, 40].
Those alterations are not typically seen in FL but are the
most common aberrations in t-FL, which suggests that they
are specifically acquired during transformation [18, 19].
& MYC aberration: MYC activation through copy number
gain, amplification, deletions, or loss of heterozygosity is
another important cell disruption in t-FL. It provides mul-
tiple advantages to lymphoma cells and supports cell
growth, metabolism, and genetic instability [18, 41].
MYC aberrations are rare at diagnosis, but are frequent-
ly found at the time of progression as well as during trans-
formation. The acquisition of MYC activation in FL in
which BCL-2 translocation has already occurred, charac-
terizes Bdouble-hit^ lymphoma. According to some au-
thors, this is the second most common genetic alteration
in t-FL [18, 41–43].
In addition to that, BCL-6 translocation, which may
also occur during transformation, characterizes Btriple-
hit^ lymphoma (MYC/BCL-2/BCL-6) and confers an
even worse prognosis [41, 44].
It is important to emphasize that MYC alterations as-
sociated with FL might have a different origin than BL,
considering that in FL, this alteration results from the co-
operation between BCL-2 and the deregulation of
activation-induced cytidine deaminase (AID), while in
BL, it is a consequence of t(8;14) translocation [45].
& Other lesions (non-phase-specific lesions):
The following alterations have heterogeneous con-
tributions to lymphoma transformation but are still the
focus of some studies [18]: (a) TNFRSF14 [14, 18],
member of TNF receptor superfamily, which functions
in T cell signaling and is disrupted in 56.4% of t-FL
cases; (b) STAT6 [18], DNA-binding transcription fac-
tor implicated in IL4- and IL3-mediated responses and
is mutated in 23.1% of t-FL cases; (c) CARD 11 and
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Fig. 1 Physiopathology of transformation. This simplified pathway that
illustrates the driving of transformation from a B cell to a transformed
follicular lymphoma (t-FL) cell. Green circles, mutated common
progenitor cells (CPCs); blue circles, follicular lymphoma (FL) cells;
red circles, transformed follicular lymphoma cells. 1-IGH/BCL-2
translocation is the first event in FL physiopathology, although it can
also occur in healthy individual cells; 2 and 3-BLinear model^ of t-FL
with subsequent accumulation of mutations. Some CPCs may still be
present in FL samples; 4- BNonlinear^ transformation (most frequent)
originates from CPCs. *P53, mutations, deletions, loss of
heterozygosity/CDKN2A; deletions and or loss of heterozygosity/
MYC; translocation, amplification, or gains
Biopsy 
1 2 3 4
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D
B
Fig. 2 Follicular Lymphoma as a
heterogeneous entity. a Classical
FL Homogenous. b Classical FL
with subpopulations (A) classical
FL, (B) localized progression, (C)
subpopulations in the same lymph
node that may have different
drivers of mutation. c
Transformed FL and reminiscent
areas of indolent lymphoma (D)
theses reminiscent areas may be
responsible for the persistence of
lymphoma after different lines of
therapy. d composite histology
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CD79B [18], alters signaling pathway responses in-
volved in the engagement of BCR and CXCR4 and is
present in 10.3% of the t-FL cases; TNFAIP3 [18],
regulator of NFkB, lost in 15% of t-FL cases; and (d)
deregulation of immune responses HLA class 1 locus
and complement (CD58) [46].
Another mechanism that has been extensively studied is the
role of somatic hypermutation (SHM) and class-switch re-
combination of the immunoglobulin gene in the B cell lym-
phomagenesis [47, 48]. These are specifically important in
lymphomas in which the germinal center is the source of the
cell of origin [47, 48]. Accumulating evidence has suggested
that lymphoma-associated translocations and the activation of
other oncogenes are initiated by AID [49].
The mistargeted activity of AID is associated with genetic
instability, cell-cycle arrest, and apoptosis [45]. It is postulated
that histone/chromatin modification enzymes (active in FL)
may permit non-physiologic genomic regions to be accessed
by AID, which leads to the generation of secondary genetic
mutations. The high expression of AID has been described to
be associated with t-FL [8, 18].
Regarding the genetic signature, t-FL appears to be closely
related to germinal center B cell (GCB)-like DLBCL, as they
share common features such as BCL-2 rearrangements, REL
amplifications, and mutations in EZH2, GNA13, and
TNFRSF14. On the contrary, t-FL shows CDKN2A/B dele-
tions, STAT6 mutations, ARID1A mutations, and FAS
mutations/deletions that are rarely seen in de novo DLBCL,
which demonstrates its specificity [18, 50].
It is important to emphasize that the majority of genetic
aberrations that are typical of t-FL can also be observed at a
lower frequency in indolent FL [18, 33]. This finding suggests
that a single alteration may not be sufficient to drive transfor-
mation and that possibly, a major disruption in the molecular
machinery is needed.
Additionally, the selective pressure for FL to undergo trans-
formation remains incompletely understood. Carlotti et al. [31]
identified clonal evolution in patients who were exposed to dif-
ferent types of treatment, including radiotherapy, chemotherapy,
and the Bwatch and wait^ regimen. Pasqualucci et al. [18] also
described that mutations do not occur only as a consequence of
treatment, considering that untreated patients had been diag-
nosed with transformation. Therefore, the mutation load should
also be considered a complex entity that does not simply reflect a
consequence of the treatment or chemotherapy [18, 31].
The complex clonal panorama of FL is consistent with its
variable and unpredictable clinical behavior [38]. FL tumor
cell populations and subpopulations may undergo multiple
Btransformations^ during their lifespan, and it is also probable
that they acquire different mutations and presumably distinct
sensitivities to therapies [11, 18, 31].
Diagnosis
A key problem in t-FL lies with its definition, which relies on
the histologic evidence of DLBCL in patients with a previous
or concomitant history of FL. Biopsy is still considered the gold
standard that is used to document the event [14, 21, 51, 52];
however, in some cases, clinical aspects can be considered con-
vincing enough to conclude that transformation has occurred
[11, 19, 51, 53]. Notably, many of the initial reports on t-FL
were based on the clinical definition of transformation, while
the most recent data rely on a stricter pathological definition.
The comparison between the cohorts is shown in Table 1.
The diagnosis of t-FL may be separated into the following
aspects:
Clinical
Higher-grade transformation should be suspected in every FL
patient who presents with progression and the fast growth of
t(14;18) IGH:BCL2
PROGRAMMED CELL DEATH-
APOPTOSIS
AID overexpression/ SHM 
CHROMATIN REMODELING 
Epigenec mechanisms
CREBBP/ EP300 
MLL2 / H3K4/ EZH2  
CELL CYCLE AND DNA DAMAGE 
PROLIFERATIONS 
CDK2A/B/ p53
CHROMOSSOMAL TRANSLOCATIONS MYC
OTHER ALTERATIONS TNFRSF14/ STAT6/ CARD11/ TNFAIP3/ CD58
B- CELL FOLLICULAR LYMPHOMA TRANSFORMED FOLLICULAR LYMPHOMA
Fig. 3 The postulated tumorigenesis of t-FL. The earliest step in the
development of FL is the acquisition of the IGH/BCL-2 translocation,
although alone, it is insufficient to produce FL as this alteration can also
be seen in the normal population. The subsequent oncogenic mutation
that produced FL is thought to be related to the mistargeted activity of
AID and to epigenetic mechanisms, especially CREBBP, MLL, EZH2,
H3K4, and others. Histological transformation is associated with later
events such as alterations in CDK2A/B, p53, and MYC. Other
alterations are also observed to be part of the transformation process
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lymph nodes, new extra-nodal sites (i.e., those in the central
nervous system, liver, and bone), the development of B symp-
toms, new hypercalcemia, or the sudden rise in lactate dehy-
drogenase (LDH). In addition, most patients present with ad-
vanced disease (stage III/IV or bulky stage I/II disease) al-
though limited disease may also be associated with transfor-
mation [8, 11, 24, 51, 54].
Additionally, time until progression is important, con-
sidering that it might be associated with early progression
(< 2 years after the start of rituximab-based regimens) and
transformation. Mozessohn et al. described that transfor-
mation was documented in 36.3% (8/22) of cases of early
progression [55].
Regarding time to transformation, it has been shown that
patients who are diagnosed with transformation early (i.e., at
the time of diagnosis or after the first 2 years of follow-up)
have better outcomes. Thus, transformation that occurs within
18 months seems to be the worst scenario, as patients exhibit a
shorter survival [19, 21].
Histopathology
FL is composed of cells that resemble normal germinal cen-
ters, while aggressive lymphomas are characterized by the
diffuse proliferation of large cells that efface the follicular
architecture [14, 56]. Biopsy with immunohistochemical ex-
amination remains the standard that is used to confirm t-FL.
The majority of the transformations show the presence of
DLBCL (93%) or BL (7%) [51]. Rare histotypes including
B lymphoblastic leukemia, plasmablastic lymphoma, and
high-grade B cell lymphoma—NOS/with MYC and BCL-2
and/or BCL-6 translocations have also been reported
[57–59].
At the time of transformation, 30% of DLBCL cases are
BCL-6-positive, and more than 10% demonstrate transloca-
tion of MYC and BCL-2 in the germinal center [60].
Furthermore, while FL has a low proliferative index, t-FL
usually has high Ki-67 expression (staining and transferrin
receptor-related protein), which indicates a high proliferative
index [56].
The WHO classification [57] also subdivides FL into four
grades based on histology (number of centroblasts). Grades 1,
2, and 3A are considered consistent with the morphological
spectrum of FL, while grade 3B is considered to be closely
related to de novo aggressive lymphoma [57]. Koch et al.
analyzed these groups separately and showed that a large pro-
portion of grade 3A FL harbored areas that resembled FL
grades 1/2. In contrast, grade 3B FL rarely coexists with grade
1/2 or 3A FL and was found to be mostly associated with
diffuse growth (DLBCL), which indicates a divergent patho-
genesis [61]. This last sub classification, however, seems to be
important since grade 3A has been linked to an increased risk
of transformation [41, 62, 63].Ta
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Moreover, it is already established that t-FL cannot be mor-
phologically distinguished from de novo DLBCL, and simi-
larly, can be divided into molecular subtypes [41]. As expect-
ed, Kridel et al. and Bousaka et al. reported that the majority of
t-FL is of the GCB phenotype and that the minority can be
identified as the activated B cell (ABC) type [41, 64]. They
also reported that the exceptional t-FL ABC subtype is BCL-
2-negative, CD10- negative, and IRF-4-positive. These rare
molecular alterations tend to co-occur to delineate a distinct
molecular pathway and possibly a different entity [41, 65].
Another histological feature of t-FL is that FL and DLBCL
can co-occur in the same lymph node and be characterized by
a composite histology. This finding implies but does not con-
firm early transformation. Some authors suggest at least a 6-
month interval between the initial FL and the DLBCL diag-
nosis to unequivocally define it as a transformation [14, 53].
Imaging
On the one hand, computed tomography (CT) can help to
determine the size of lymph nodes, but this type of scan does
not show the metabolic activity of the disease [66]. On the
other hand, [18F] fluorodeoxyglucose (FDG)-positron emis-
sion tomography (PET-CT) has emerged as a powerful func-
tional imaging tool for staging and response assessment in
Hodgkin lymphoma and DLBCL [13, 67, 68].
The Lugano classification recently included PET in the
response assessment for indolent lymphoma subtypes, such
as FL [69, 70]. Metabolic response, as defined by PET-CT,
was demonstrated to be a strong predictor of OS and PFS after
R-induction therapy, and this riskwas found to be independent
of the FLIPI and FLIPI-2 scores [71].
18F-FDG avidity was also described to be correlated with
proliferation levels (Ki-67 expression). A high-standardized
uptake value (SUV) on PET-CT in FLmay suggest aggressive
disease and possible transformation into DLBCL [72]. Studies
of indolent lymphomas have reported that an SUV > 10 could
predict aggressive lymphoma histology with 80% certainty, an
SUV > 13 with 90% certainty and an SUV > 17 with 100%
certainty [73, 74]. Moreover, patients with DLBCL and t-FL
showed similar SUV rates [11, 66]. Noy et al. described that
the SUVs in biopsy-proven sites of transformation had a me-
dian value of 12 but ranged widely from 3 to 38. Although the
majority of the transformations were associated with a high
SUV in this study, many were not. Therefore, transformation
might be suspected but not proven with PET-CT. These au-
thors also reaffirmed the recommendation of biopsies of sites
with the highest FDG uptake [75].
More importantly, according to this new concept of
PET-directed biopsy, it is likely that in the near future, an
increasing number of t-FL will emerge; however, the clin-
ical meaning of the discovery of hidden t-FL is not clear
and warrants future investigation.
Risk of transformation
Histological transformation, which remains a rare event in the
natural history of FL, ranges from 4 to 27% (Table 1), and the
identification of reliable predictors of transformation at the
time of FL diagnosis remains a challenge. The identification
of patients who are at high risk for transformation would allow
appropriate monitoring, effective treatment, and the develop-
ment of potential novel therapeutic approaches. Evidence
from the literature regarding risk factors of t-FL can be divided
into clinical, therapeutic, pathological, and genetic features.
Clinical and treatment-related risk factors
Until now, clinical factors have been the most important fea-
tures that are used to predict the risk of transformation [15]
(Table 2). The items already described are: elevated beta-2-
microglobulin levels, high IPI, high FLIPI, and advanced
stage (III and IV) [24, 51, 53, 76]. The most recent studies,
which were conducted during the rituximab era, described
LDH, anemia, an Eastern Cooperation Oncology Group
(ECOG) performance status > 1, and high FLIPI as indepen-
dent risk factors for transformation [15, 19, 21, 77].
Furthermore, Conconi et al. affirmed the importance of bulky
mass and extra-nodal disease, while Sarkozy et al. also sug-
gested B symptoms and histological grade 3A as predictors of
transformation [15, 77].
With regard to time as a risk factor, some authors have
described that transformation seems to be an early event in
the natural history of FL, while progression shows a linear risk
over time [15, 53]. Sarkozy described that more than half of
HTs in FL were documented during the first year after induc-
tion; Link et al. reported a reduction in the risk of HT after
5 years of follow-up [15, 19, 53]. In contrast, other groups
have suggested that the risk of transformation over time ap-
pears uniform, at least during the first 15 years of follow-up
[51, 53]. Until now, it has not been possible to conclude
whether the risk of HT is time-dependent since studies have
used different patterns for follow-up, inclusion criteria, and
treatments [15].
Different treatment approaches have also been evaluated
as risk factors for HT such as expectant management, num-
ber of therapies, anthracycline use, and rituximab use.
Considering that Bwatch and wait^ is a first-line therapy
for FL, Montoto et al., Link et al., and Wagner-Johnston
et al. have described that the transformation rates were
higher among patients who were primarily observed than
those who were initially treated. On the contrary, Conconi
et al. found that the Bwatch and wait^ approach was asso-
ciated with a lower risk of transformation, [19, 21, 24, 77]
while Ardeshna et al. in a randomized trial, observed that
the risk of transformation was similarly low between the
two study arms (observation vs. rituximab) [78].
Ann Hematol
With respect to treatment outcomes, patients were de-
scribed to be at a higher risk if they did not achieve complete
response at the end of induction therapy [53, 76]. However,
Sarkozy et al. described that the quality of the response did not
impact the risk of transformation [15]. In addition, no consen-
sus exists in the literature regarding the use of anthracycline.
Some authors have suggested no correlation [15, 19, 21],
while others have reported lower risk with the use of this drug
[51].
Rituximab, as part of induction therapy and based on either
retrospective [19, 21, 51, 79] or clinical trials data [15], has been
suggested to reduce the risk of transformation, especially when
used as a maintenance therapy. These latest studies clarified
previous questionswith respect to the benefits of rituximab [78].
Pathological and genetic risk factors
Pathological and genetic factors are emerging as novel predic-
tors of risk, but the literature remains contradictory in some
aspects, and these new biomarkers need to be validated in
large prospective cohorts [33].
Considering the pathological findings, the grading of FL
has been associated with survival and transformation. Despite
this, high-grade FL has historically been associated with poor
survival [57], but the most recent studies have shown a better
outcome for grade 3A/B FL [80]. Grade 3A has also been
linked to an increased incidence of transformation in some
studies, and both 3A/B have been associated with certain mo-
lecular findings that have been described as risk factors for
transformation, such as BCL-6 translocation, absence of pro-
totypical BCL-2 translocation, and/or positive expression of
IRF4 [41, 62, 63].
The immunohistochemical assessment of IRF4 warrants
special attention since it is associated with a worse prognosis,
poor progression-free survival (PFS), high proliferation rates,
and transformation [41, 63, 81]. This protein deserves further
validation but has a plausible potential to predict transforma-
tion [33].
Genetic features represent another means to predict trans-
formation risks. The alterations that have been described in the
literature thus far are chromosomal changes (i.e., segmental
deletions within 1p and 6p or gains involving 2, 3q, and 5)
[82–85], somatic gene mutations such as those in the BCL-6
gene [86] and BCL-2 gene [8, 87] and MYC rearrangements
[43]. Other alterations include the loss of heterozygosity or
mutations in Tp53 [88, 89], deregulation of MDM2 (key
p53 regulator) [88], and inactivation of CDKN2A/B by dele-
tion mutations and hypermethylation [90].
Table 2 Risk factors for transformation
First author, year (database) Risk factors at diagnosis Other risk factors
Before rituximab era Bastion, 1997 High B2microglobulin1;
low albumin levels
Less than CR at the end of
treatment induction
Giné, 2006 Grade 3 histology1;
nodal areas > 4;
high LDH;
high B2microglobulin;
high IPI;
high FLIPI1
Less than CR at the end of
treatment induction
Montoto, 2007 Advanced stages;
high FLIPI;
high IPI
Expectant management as
initial therapy
Al-Tourah, 2008 (Lymphoid
Cancer-British Columbia)
Advanced stage1 Multiples lines of therapy alkylator
with purine analogue
After rituximab era Conconi, 2012 Bulky1;
extranodal disease1
R-chemo increased the risk
Link, 2013 LDH1;
anemia (Hb < 12);
FLIPI
Expectant management as
initial therapy
Wagner-Johnston, 2015
(National Lymphoma Care)
ECOG > 11; extranodal sites > 11;
high LDH1; B symptoms1
Expectant management as
initial therapy
Sarkozy, 2016 (PRIMA) ECOG1;
anemia1;
high LDH;
B symptoms;
high FLIPI score;
grade 3A
CR complete response, LDH lactate dehydrogenase, IPI International Prognostic Index, FLIPI Follicular Lymphoma International Prognostic Index
1 Independent factors in multivariate analysis
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As has been described previously, other individual genes
have also been studied. Consequently, Pastore et al. proposed
a risk model (m7-FLIPI) that combines the mutational status
of seven genes (EZH2, ARID1A, MEF2B, EP300, FOXO1,
CREBBP, and CARD11) into a predictive score that also in-
cludes the FLIPI and ECOG performance status. This model
introduces a new concept for risk stratification in FL and is a
promising approach that may be used to identify the subset of
FL patients at highest risk for treatment failure. Although no
data have been generated regarding transformation in this risk
model, m7-FLIPI may be a promising marker that can be used
in risk stratification for transformation [33, 91].
Treatment
Treatment and outcome in historical series
In initial studies, the outcome of t-FL patients was very poor,
with a median OS of approximately 1 or 2 years [24]. However,
the majority of published studies were conducted in the pre-
rituximab era. Most recent studies have confirmed the improve-
ment of OS in patients with t-FL in the rituximab era (as part of
induction and post-transformation therapy) [19, 53, 79].
The study conducted by Link and colleagues found that in
60 out of 631 patients with biopsy-proven t-FL, the OS rate
was 73% at 5 years after treatment with rituximab-based che-
motherapy [18]. The results seen in patients with early-stage
FL (treated with radiotherapy only) who experienced transfor-
mation were equivalent. The 3-year OS post-transformation
was 87 vs. 38.5% for R-chemotherapy and chemotherapy
alone, respectively [92].
The R-CHOP regimen is still currently considered a good
option with which to treat t-FL, especially anthracycline-naïve
patients. It is known that some t-FL cohorts have responded
extremely well with only R-chemotherapy [19, 21, 93].
Additionally, Link et al. showed that after transformation,
the outcomes were indistinguishable when compared with
those of patients with de novo DLBCL and anthracycline-
naïve transformed FL [19].
Therefore, the role of autologous stem cell transplantation
(ASCT) in the rituximab era does not seem to be mandatory
[19]. Wagner-Johnston et al. reported that only a few t-FL
patients have undergone ASCT, which reaffirms this idea
[21, 94].
Despite the controversy surrounding ASCT, this therapy
can be considered part of the treatment for eligible patients
with t-FL, especially those who have already been exposed
to anthracyclines. In studies from the pre-rituximab era, in
patients with chemosensitive transformed lymphoma, the
5-year OS and PFS rates after ASCT were 51 and 30%,
respectively, which suggests a long-term benefit of this
management strategy [95].
With regard to ASCT in the rituximab era, this approach
has been shown to improve the outcomes of t-FL in some
studies; Table 3 summarizes the major studies that have been
conducted in the rituximab era. The Canadian Bone Marrow
Transplant Group (CBMTG) showed better outcomes (OS
and PFS) for those treated with additional ASCT, even though
this difference was modest at 5 years (OS 65% with ASCT;
61% with chemoimmunotherapy; p < 0.001) [96].
Ban-Hoefen et al. (NCCN database) also suggested a ben-
efit of ASCT in the rituximab era. The 2-year OS was 74% for
patients who underwent ASCT, while for those who did not,
the 2-year OS was 59%. This group also emphasized that
patients who were chemotherapy-naïve prior to ASCTseemed
to achieve better results [22].
For post-ASCT relapses, a few options exist including nov-
el regimens (in the context of clinical trials) and possibly sal-
vage therapy with allogeneic transplantation (AlloSCT) for
highly selected patients [97, 98]. However, AlloSCT in t-FL
has not been well-studied, and studies to date have been
Table 3 Studies that have evaluated ASCT or allogeneic transplant in transformed follicular lymphoma in the rituximab era
First author, year (database) ASCT or allo Number
of patients
Median age at
transplantation
(years)
OS,
(%)
PFS or EFS,
(%)
Median follow-up
(years)
Smith, 2009 ASCT 25 57 3 years, 63 3 years, 64 2.1
Reddy, 2012 ASCT 12 61 5 years, 91.7 5 years, 73.3 6
Allo 23 52 5 years, 53.9 5 years, 43 6
Ban-Hoefen, 2012
(National Comprehensive Cancer
Network-Database)
ASCT 181 58 2 years, 82 2 years, 59 3.3
Villa, 2013
(Canadian Bone Marrow
Transplant Group)
ASCT 97 56 5 years, 65 5 years, 55 7.5
Allo 22 48 5 years, 46 5 years, 46 7.5
OS overall survival, PFS progression-free survival, EFS event-free survival
1 Included two patients with marginal zone lymphoma and six patients did not received rituximab as an induction therapy
Ann Hematol
performed in small cohorts and have involved short follow-
ups and significant transplant-related mortality. Reddy et al.
compared AlloSCT to ASCT and observed an important dif-
ference between these groups. The 5-year post-transplant OS
was 53 vs. 91.7%, while the PFS was 43 vs. 73.3%, for the
AlloSCT and ASCT groups, respectively. However, Villa
et al. (Canadian Bone Marrow Transplant Group) described
an OS of 46 vs. 65% and a PFS of 46 vs. 55% for the AlloSCT
and the ASCT groups, respectively, at 5-year post-transplant
[96, 99]. Therefore, the AlloSCT series demonstrated an infe-
rior result compared with that of ASCT, which was due in part
to high treatment-related mortality (35 vs. 10% at 5 years,
respectively) and also to heavily pre-treatment conditions
[100]. On the contrary, the risk for disease relapse at 5 years
was lower in the AlloSCT group, but it is important to con-
sider that those patients comprised a highly selected group
[22].
Current management
Our approach to the management of t-FL begins with the
correct diagnosis, which reinforces the importance of biopsy
at the time transformation is suspected. A PET-CT-guided
biopsy may be useful in this scenario. After the diagnosis is
confirmed, subsequent decisions would be made based on the
age, comorbidities, and performance status of the patient. In
both young and old patients who are physically fit, it is im-
portant to clarify whether they have been exposed to previous
treatments with anthracycline-based regimens. If patients
were previously exposed, they should undergo salvage che-
motherapy (platinum-containing chemotherapy) and ASCT;
however, if the patients are anthracycline-naïve, they should
receive R-CHOP. ASCT can be discussed, but it is not man-
datory. For older unfit patients who have received
anthracycline or are too frail to tolerate full-dose chemothera-
py, the regimens suggested are mini-CHOP [101] or non-
anthracycline-containing regimens such R-GCVP [102].
Clinical trials are strongly encouraged in this situation, espe-
cially with the new available single-agent lenalidomide [103],
venetoclax [104], ibrutinib [105], and idelalisib [106, 107].
Novel regimens
Novel agents have also been investigated in t-FL. In a phase 2
study, lenalidomide showed an overall response rate of 57%,
with a median response duration of over 1 year in t-FL patients
[103]. Specific inhibitors that target Aurora A kinase
(alisertib) [108], Bruton tyrosine kinase (ibrutinib) [105], the
ϑ isoform of phosphatidylinositol 3-kinase (idelalisib) [106,
107], and BCL-2 protein (GDC-0199/ABT199—venetoclax)
[104] are currently being investigated in both indolent and
aggressive lymphomas. These novel agents seem to have a
significant impact on the outcome of t-FL patients.
Conclusion
HTof indolent lymphoma has been randomly studied over the
years, and even now, many are concerned considering the
morbidity and mortality rates of t-FL. The incidence varies
among different series and according to different definitions
of HT and treatment approaches. Most available data are de-
rived from retrospective studies, whereas risk factors and ther-
apeutic strategies are not completely standardized.
Furthermore, the most recent data suggest that rituximab (in-
duction or maintenance) is associated with better outcomes
and lower risks of transformation. Further studies are still
necessary to clarify the biology of transformation as well as
the identification of biomarkers, which might be future poten-
tial targets for individualized treatment of t-FL.
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